XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Marketable Securities
9 Months Ended
Sep. 30, 2021
Marketable Securities [Abstract]  
Marketable Securities
NOTE 3. MARKETABLE SECURITIES
Marketable securities consisted of the following as of September 30, 2021 (in thousands):
 
    
Amortized
Cost
    
Gross Unrealized
Gains
    
Gross Unrealized
Losses
    
Fair
Value
 
Available-for-sale
securities, short-term
                                   
Commercial paper
   $ 43,923      $ —        $ —        $  43,923  
Corporate debt securities
     8,043        —          (2      8,041  
Asset-backed securities
     12,200        —          (2      12,198  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
available-for-sale
securities, short-term
     64,166        —          (4      64,162  
Available-for-sale
securities, long-term
                                    
Corporate debt securities
     16,866        —          (20      16,846  
Asset-backed securities
     7,080        —          (4      7,076  
U.S. treasury securities
     5,988        —          —          5,988  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
available-for-sale
securities, long-term
     29,934        —          (24      29,910  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
available-for-sale
securities
   $  94,100      $ —        $ (28    $ 94,072  
    
 
 
    
 
 
    
 
 
    
 
 
 
As of September 30, 2021, the Company’s
available-for-sale
securities classified as short-term mature in one year or less and the Company’s
available-for-sale
securities classified as long-term mature within two years. All of the Company’s
available-for-sale
marketable securities in an unrealized loss position as of September 30, 2021 were in a loss position for less than twelve months. Unrealized losses on
available-for-sale
securities as of September 30, 2021 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, no other-than-temporary impairment was recorded for the three and nine months ended September 30, 2021. The Company does not intend to sell these securities and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.